Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
25
datasets available to search
ShareScore release 0.9.0
Dataset results
25 results for “interferon lambda”
Pegylated Interferon Lambda Treatment for COVID-19
ClinicalTrials.gov study NCT04343976. IPD Sharing: YES. Countries: 1. Publications: 1.
A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection
ClinicalTrials.gov study NCT02765802. IPD Sharing: Not stated. Countries: 3. Publications: 3.
Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV
ClinicalTrials.gov study NCT01866930. IPD Sharing: Not stated. Countries: 12. Publications: 1.
Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19
ClinicalTrials.gov study NCT04354259. IPD Sharing: NO. Countries: 2. Publications: 3.
Interferon-lambda: Novel Biologics for Controlling Neutrophil-mediated Pathology in Rheumatic Diseases?
ClinicalTrials.gov study NCT02498808. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen
ClinicalTrials.gov study NCT01204762. IPD Sharing: Not stated. Countries: 11. Publications: 2.
Data from: Evolutionary insights of interferon Lambda genes in Tetrapods
Open the record for dataset details and reuse information.
PERVASIVE ADAPTATION OF HEPATITIS C VIRUS TO INTERFERON LAMBDA POLYMORPHISM ACROSS MULTIPLE GENOTYPES
<p>Genetic polymorphism in the interferon lambda (IFN-λ) region is associated with spontaneous clearance of hepatitis C virus (HCV) infection and with response to interferon-based antiviral treatment. Here, we evaluate the associations between IFN-λ polymorphism and HCV variation by performing a genome-to-genome analysis in 8,729 patients from diverse ancestral backgrounds infected with various HCV genotypes. We searched for associations between human rs12979860 genotype, a tag for IFN-λ haplotypes, and amino acid variants in the NS3, NS4A, NS5A and NS5B proteins of HCV. We report multiple associations between host and pathogen variants in the full cohort as well as in subgroups defined by viral genotype and human ancestry. We also assess the combined impact of human and HCV variation on pre-treatment viral load. By demonstrating that IFN-λ genetic variation leaves a large footprint in the viral genome, this study provides strong evidence of pervasive viral adaptation to host innate immune pressure during chronic HCV infection.</p>
Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon
ClinicalTrials.gov study NCT03600714. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Interferon Lambda Therapy for COVID-19
ClinicalTrials.gov study NCT04388709. IPD Sharing: NO. Countries: 0. Publications: 1.
Macrophage coordination of the interferon lambda immune response
Open the record for dataset details and reuse information.
Cell-intrinsic regulation of phagocyte function by interferon lambda during pulmonary viral, bacterial super-infection
GEO Series GSE268994. Mus musculus. 9 samples. Type: Expression profiling by high throughput sequencing.
Phospholipid Scramblase 1 (PLSCR1) Regulates Interferon-Lambda Receptor 1 (IFN-λR1) and IFN-λ Signaling in Influenza A Virus (IAV) Infection
GEO Series GSE307868. Mus musculus. 6 samples. Type: Expression profiling by high throughput sequencing.
Interferon lambda promotes immune dysregulation and tissue inflammation in TLR7-induced lupus [scRNA-seq]
GEO Series GSE142637. Homo sapiens; Mus musculus. 6 samples. Type: Expression profiling by high throughput sequencing.
Interferon lambda restricts West Nile virus neuroinvasion by enhancing integrity of the blood-brain barrier
GEO Series GSE64735. Mus musculus. 3 samples. Type: Expression profiling by high throughput sequencing.
Data from: Lambda interferon restructures the nasal microbiome and increases susceptibility to Staphylococcus aureus superinfection
Much of the morbidity and mortality associated with influenza virus respiratory infection is due to bacterial coinfection with pathogens that colonize the upper respiratory tract such as methicillin-resistant Staphylococcus aureus (MRSA) and Streptococcus pneumoniae. A major component of the immune response to influenza virus is the production of type I and III interferons. Here we show that the immune response to infection with influenza virus causes an increase and restructuring of the upper respiratory microbiota in wild-type (WT) mice but not in Il28r−/− mutant mice lacking the receptor for type III interferon. Mice lacking the IL-28 receptor fail to induce STAT1 phosphorylation and expression of its regulator, SOCS1. Il28r−/− mutant mice have increased expression of interleukin-22 (IL-22), as well as Ngal and RegIIIγ, in the nasal cavity, the source of organisms that would be aspirated to cause pneumonia. Proteomic analysis reveals changes in several cytoskeletal proteins that contribute to barrier function in the nasal epithelium that may contribute to the effects of IL-28 signaling on the microbiota. The importance of the effects of IL-28 signaling in the pathogenesis of MRSA pneumonia after influenza virus infection was confirmed by showing that WT mice nasally colonized before or after influenza virus infection had significantly higher levels of infection in the upper airways, as well as significantly greater susceptibility to MRSA pneumonia than Il28r−/− mutant mice did. Our results suggest that activation of the type III interferon in response to influenza virus infection has a major effect in expanding the upper airway microbiome and increasing susceptibility to lower respiratory tract infection.
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
ClinicalTrials.gov study NCT01309932. IPD Sharing: Not stated. Countries: 9. Publications: 0.
Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C
ClinicalTrials.gov study NCT01447394. IPD Sharing: Not stated. Countries: 20. Publications: 0.
Pegylated Interferon Lambda for Treatment of COVID-19 Infection
ClinicalTrials.gov study NCT04534673. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
ClinicalTrials.gov study NCT01795911. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.